title: Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.
abstract: To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."
authors.affiliation: Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States.
authors.forename: Andy
authors.initials: A
authors.lastname: Kilianski
authors.affiliation: Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States. Electronic address: sbaker1@lumc.edu.
authors.forename: Susan C
authors.initials: SC
authors.lastname: Baker
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology; D002460:Cell Line; D017934:Coronavirus / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: Antivirals; Entry inhibitors; MERS-CoV; Replicase inhibitors; SARS-CoV; pGlo